Skip to main content

Selected Grants


TAK-573-1501

Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2022 - 2027

Duke ACS Institutional Research Grant

ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026

Hematology & Transfusion Medicine (T32)

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026

Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer

ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2025

Role of SLAMF7 in Racial Disparities in Myeloma

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2023 - 2025

TAK-573-1501

Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2022 - 2027

Duke ACS Institutional Research Grant

ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026

Hematology & Transfusion Medicine (T32)

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026

Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer

ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2025

Role of SLAMF7 in Racial Disparities in Myeloma

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2023 - 2025

Role of Tumor-mediated Innate Training in the Pathogenesis of Immune-related Adverse Events

ResearchCollaborator · Awarded by Cancer Research Institute · 2022 - 2024

R21 Enhancing CAR T therapy in multiple myeloma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2024

A Precision Oncology Micro-Organosphere-Based Platform to Guide Multiple Myeloma Therapy

ResearchPrincipal Investigator · Awarded by Xilis, Inc. · 2022 - 2023

Thioredoxin, a novel agent for mitigating radiation-induced hematopoietic injury

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2023

Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer

ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2023

THIOREDOXIN REGULATES P53 TRANSCRIPTION IN HEMATOPOIETIC STEM CELLS

ResearchPrincipal Investigator · Awarded by American Society of Hematology · 2022 - 2023

Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis

ResearchCo Investigator · Awarded by Department of Defense · 2018 - 2022

Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myeloma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2021

Targeting sphingosine kinase 2 for the treatment of multiple myeloma

Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2021

Clinical characteristics, JAK2 status, and macrophage infiltration in multiple myeloma patients with marrow fibrosis

ResearchPrincipal Investigator · Awarded by Incyte Corporation · 2017 - 2020

Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma

ResearchPrincipal Investigator · Awarded by Apogee Biotechnology Corporation · 2015 - 2019

Ph III study to evaluate the safety of ALN-TTR02 in TTR-Medicated Polyneuropathy

Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2014 - 2018

Thioredoxin for radioprotection

ResearchPrincipal Investigator · Awarded by Columbia University · 2016 - 2018

Develop and Support of the RedCap database, bio-statistic analysis, and med writing for Dr Kang NIH SBIR award Clin Trial

ResearchPrincipal Investigator · Awarded by RedHill Biopharma Ltd. · 2016 - 2018

Plerixafor for allogeneic hematopoietic stem cell transplantation

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2016

External Relationships


  • American Association for Cancer Research
  • Blue Bird
  • OrPro Therapeutics Inc
  • PSI Pharma Support American Inc
  • Sanofi
  • American Association for Cancer Research
  • Blue Bird
  • OrPro Therapeutics Inc
  • PSI Pharma Support American Inc
  • Sanofi
  • Xilis, Inc

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.